Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4 + T-cell Counts
- 1 April 2007
- journal article
- clinical trial
- Published by SAGE Publications in Antiviral Therapy
- Vol. 12 (3) , 325-334
Abstract
Introduction: It is unknown whether the increased risk of toxicities in antiretroviral-naive HIV-infected patients initiating nevirapine-based (NVPc) combination antiretroviral therapy (cART) with high CD4 + T-cell counts is also observed when NVPc is initiated in cART-experienced patients. Patients and methods: 1,571 EuroSIDA patients started NVPc after 1/1/1999, with CD4 + T-cell counts and viral load measured in the 6 months before starting treatment, and were stratified into four groups based on CD4 + T-cell counts at initiation of NVPc (high [H], >400/mm 3 or >250/mm 3 for male or female, respectively, or low [L], ≤400/mm 3 or ≤250/mm 3 for male or female) and prior antiretroviral experience (antiretroviral-naive [N] or -experienced [E]). Cox proportional hazards models compared the risks of discontinuation of nevirapine due to toxicities or patient/physician choice (TOXPC). Results: After adjustment, there was a significantly lower risk of discontinuation of nevirapine due to TOXPC in the HE group ( n=588; proportion discontinued by 3/12 months: 10/17%, respectively) than in HN (n=62; 21/32% respectively; overall relative hazard [RH]: 0.56; 95% confidence interval [CI]: 0.34–0.94; P=0.027). This difference was most pronounced during the first 3 months of NVPc (RH: 0.44; 95% CI: 0.23–0.87; P=0.017). There were no deaths in the 6 months after starting NVPc resulting from exposure to + T-cell counts.Keywords
This publication has 13 references indexed in Scilit:
- Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countriesThe Lancet, 2006
- Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?Antiviral Therapy, 2005
- Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell countsAIDS, 2005
- Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugsAIDS, 2005
- Hepatotoxicity Associated With Nevirapine UseJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyThe Lancet, 2004
- Drug-Induced Liver Injury Associated with the Use of Nonnucleoside Reverse-Transcriptase InhibitorsClinical Infectious Diseases, 2004
- Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmuL)HIV Medicine, 2004
- Decline in the AIDS and death rates in the EuroSIDA study: an observational studyThe Lancet, 2003
- Severe Hepatic Failure Related to Nevirapine TreatmentClinical Infectious Diseases, 1999